Hyaluronan reduces inflammation in experimental arthritis by modulating TLR-2 and TLR-4 cartilage expression  by Campo, Giuseppe M. et al.
Biochimica et Biophysica Acta 1812 (2011) 1170–1181
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r.com/ locate /bbadisHyaluronan reduces inﬂammation in experimental arthritis by modulating TLR-2 and
TLR-4 cartilage expression
Giuseppe M. Campo a,⁎, Angela Avenoso a, Giancarlo Nastasi a, Antonio Micali b, Vera Prestipino a,
Mario Vaccaro c, Angela D'Ascola a, Alberto Calatroni a, Salvatore Campo a
a Department of Biochemical, Physiological and Nutritional Sciences, Section of Medical Chemistry, School of Medicine, University of Messina, Policlinico Universitario, 98125 Messina, Italy
b Department of Biomorphology and Biotechnology, School of Medicine, University of Messina, Policlinico Universitario, 98125 Messina, Italy
c Institute of Dermatology, School of Medicine, University of Messina, Policlinico Universitario, 98125 Messina, Italy⁎ Corresponding author at: Department of Biochemica
Sciences, School of Medicine, University of Messina, P
Biologica, 5° piano, Via C. Valeria, 98125 Messina, Ita
fax: +39 090 221 3898.
E-mail address: gcampo@unime.it (G.M. Campo).
0925-4439/$ – see front matter © 2011 Elsevier B.V. A
doi:10.1016/j.bbadis.2011.06.006a b s t r a c ta r t i c l e i n f oArticle history:
Received 1 April 2011
Received in revised form 16 May 2011
Accepted 13 June 2011
Available online 21 June 2011
Keywords:
NF-kB
Toll-like receptor
Cytokine
TNF-alpha
Arthritis
HyaluronanPrevious studies have reported that low molecular mass HA and highly polymerized HA respectively elicited
pro- and anti-inﬂammatory responses by modulating the toll-like receptor 4 (TLR-4) and the TLR-2. The
activation of TLR-4 and TLR-2 mediated by collagen-induced arthritis (CIA) induces the myeloid
differentiation primary response protein (MyD88) and the tumor necrosis factor receptor-associated factor
6 (TRAF6), and ends with the liberation of NF-kB which, in turn, stimulates pro-inﬂammatory cytokine
production. The aim of this study was to investigate the inﬂuence of high molecular weight HA at different
concentrations on TLR-4 and TLR-2 modulation in CIA in mice. Arthritis was induced in mice via intradermal
injection of an emulsion containing bovine type II collagen in complete Freund's adjuvant. Mice were treated
with HA intraperitoneally daily for 30 days. CIA increased TLR-4, TLR-2, MyD88 and TRAF6 mRNA expression
and the related protein in the cartilage of arthritic joints. High levels of both mRNA and related protein were
also detected for tumor necrosis factor alpha (TNF-α), interleukin 1-beta (IL-1-β), interleukin-17 (IL-17),
matrix metalloprotease-13 (MMP-13) and inducible nitric oxide synthase (iNOS) in the joint of arthritic mice.
HA treatment signiﬁcantly limited CIA incidence and decreased all the parameters up-regulated by CIA. The
improvement of biochemical parameters was also supported by histological analysis, plasma and synovial
ﬂuid HA levels. These results suggest that the TLR-4 and TLR-2 play an important role in the arthritis
mechanism and the interaction/block of HA at high molecular mass may reduce inﬂammation and cartilage
injury.l, Physiological and Nutritional
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Rheumatoid arthritis (RA) is a chronic systemic inﬂammatory
disease leading to joint inﬂammation, functional disability, deformi-
ties, and shortened life expectancy [1].
The hallmark of RA is synovial inﬂammation which directly drives
extracellular matrix (ECM) degradation with consequent joint
cartilage destruction and bone alterations [2]. In RA the synovial
inﬂammation induces a disturbance in the regulation of anabolic and
catabolic activities of cartilage. The end result is a net loss of cartilage
with deterioration of its structural and functional properties. The
factors inﬂuencing cartilage breakdown are invasion cells such as
resident cells of the joint, in particular synovial ﬁbroblasts, or
activated macrophages, together with their inﬂammatory productssuch as cytokines, chemokines and proteinases including metallopro-
teases (MMPs) [2,3].
Previous studies reported that pro-inﬂammatory cytokines pro-
duced by the synovial tissues from arthritic joints involve the
activation of several TLRs [4–6]. Further investigations demonstrated
that it is the TLR-4 and TLR-2 that particularly seem to be deeply
involved in the mediation of the inﬂammatory mechanisms of
arthritis and which in the end lead to synovial inﬂammation and
the consequent cartilage erosion [7–9].
Hyaluronan (HA) is a non-sulfated major glycosaminoglycan
(GAG) of the ECM that has been shown to undergo rapid degradation
at inﬂammation sites resulting in the accumulation of lower
molecular weight HA fragments [10,11]. It has been reported that
low molecular weight degradation products of HA may elicit various
pro-inﬂammatory responses, such as the activation of murine alveolar
macrophages [12]. Other reports showed that low molecular weight
HA oligosaccharides induce a complete and irreversible phenotypic
and functional maturation of human dendritic cells, while high
molecular weight HA has no such effect [13]. Of particular interest is
the evidence that the activation of the TLR is not limited solely to
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alternative ligands [14]. Among these, HA is described as an
interacting agent capable of exerting different effects [15–17].
Interestingly, the effect of HA on the inﬂammatory response activated
by TLRs, especially TLR-4 and TLR-2, appears to be related to its
molecular size, i.e. high molecular weight hyaluronan has anti-
inﬂammatory activity [18–24] while small hyaluronan fragments
have pro-inﬂammatory activity [15–17,25]. About the protective
action of high molecular mass HA, a series of different hypotheses has
been postulated by several authors, however the exact mechanism
seems to be yet unclear [18–24].
Accordingly, armed with these ﬁndings, and since in our previous
in vitro studies we have found an involvement of TLR-4 and the
consequent NF-kB inhibition, exerted by highmolecular weight HA, in
chondrocytes stimulated with lipopolysaccharide (LPS) [18,26], the
aim of the present study was to investigate, using a CIAmodel in mice,
whether the chronic administration of high molecular weight HA, as
previously evaluated in CIA in rats [27,28], involves TLR-2, TLR-4 and
NF-kB modulation.
2. Materials and methods
2.1. Animals
Male mice DBA/J1 6–7 weeks old with a mean weight of 25–30 g
were used in our study. Mice, purchased from Harlan (Correzzana,
Italy), were maintained under climate-controlled conditions with a
12-h light/dark cycle. The animals were fed standard rodent chow and
provided water ad libitum. The health status of the animal colony was
monitored in accordance with Italian Veterinary Board guidelines.
Mice were divided into the following groups: 1) Control (n=17); 2)
HA (40 mg/kg) (n=17); 3) CIA (n=27); 4) CIA+HA (10 mg/kg)
(n=23); 5) CIA+HA (20 mg/kg) (n=23); and 6) CIA+HA
(40 mg/kg) (n=23). Two additional sets of mice (n=7 for each
group) were considered in order to evaluate HA levels in plasma and
synovial ﬂuid. One set of mice was sacriﬁced at day 35, while the
second set was sacriﬁced at day 50.
2.2. Materials
Highmolecular weight HA (4000 kDa) was purchased from Sigma-
Aldrich Srl, (Milan, Italy). The compound was endotoxin free
(endotoxin content b0.1 ng/mg). Bovine type II collagen and complete
Freund's Adjuvant were obtained from MD Biosciences (Zurich,
Switzerland). Mouse TNF-α (cat. IB49688), IL-1β (cat. IB49700), and
IL-17 (cat. IB49699) commercial ELISA kits were provided by Immuno-
Biological laboratories Inc. (Minneapolis, MN, USA). Mouse MMP-13
(cat. E0099m) and iNOS (cat. E0837Mu) commercial ELISA kits were
obtained from USCN Life Science Inc. Wuhan (Wuhan, China). Rabbit
TLR-4 (cat. sc-30002), TLR-2 (cat. sc-10739),MyD88 (cat. sc-11356) and
TRAF6 (cat. sc-7221) polyclonal antibodies and horseradish peroxidase-
labeled goat anti-rabbit antibodies (cat sc-2004) were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). All other reagents used
were purchased from Fluka (division of Sigma-Aldrich Srl, Milan, Italy).
2.3. Induction of CIA and arthritis evaluation
Mice were injected intradermally, at the tail base, with 100 μL of
2.0 mg/mL type II collagen emulsion in Freund's complete adjuvant
containing 2.5 mg/mL heat-killed Mycobacterium tuberculosis H37Ra.
Mice were immunized a second time 7 days later.
Evaluation of joint inﬂammation was carried out blindly by an
independent observer with no knowledge of the treatment protocol.
The severity of the arthritis in each limb was graded daily on a scale of
0–4 as follows: 0, no macroscopic signs of arthritis; 1, swelling of one
group of joints (i.e. wrist or ankle joints); 2, two groups of swollenjoints; 3, three groups of swollen joints; and 4; swelling of the entire
limb. The maximum score for each mouse was 16. Clinical severity
was also assessed by quantifying changes in limb volume. Measure-
ments were performed using a dial gage caliper. At the end of the
experimental period (day 50) mice were anesthetized with ethyl
ether and then sacriﬁced to remove their hind limbs.
2.4. HA treatment
On day 20, to coincide approximately with the CIA onset, the
animals were randomized to receive the treatments listed above in
the Animals section. HA was dissolved in saline solution (0.9% NaCl)
and administered intraperitoneally using a volume of 1.0 mL/kg body
weight, once a day up until day 50.
2.5. Cartilage isolation from mice joint
At the end of the experimental phase (day 50)micewere sacriﬁced
by cervical dislocation and the whole hind limbs isolated from the
body. One knee joint was conserved for histological examination, the
remaining knee joint and the two paw joint were dissected and the
total cartilage was separated from bone and muscular tissue, washed
in ice-cold 10 mM Tris–HCl, pH 7.4, and blotted on absorbent paper.
These operations were performed on cooled support refrigerated on
dry ice. Whole cartilage was immediately stored on liquid nitrogen
until biochemical assay.
2.6. RNA isolation, cDNA synthesis and real-time quantitative PCR
ampliﬁcation
Total RNA was isolated from cartilage tissue for reverse-PCR real
time analysis of TLR-4, TLR-2, MyD88, TRAF6, TNF-α, IL-1β, IL-17,
MMP-13 and iNOS (RealTime PCR system, Mod. 7500, Applied
Biosystems, Carlsbad, CA, USA) using an Omnizol Reagent Kit
(Euroclone, West York, UK). The ﬁrst strand of cDNA was synthesized
from 1.0 μg total RNA using a high capacity cDNA Archive kit (Applied
Biosystems, Carlsbad, CA, USA). β-actin mRNA was used as an
endogenous control to allow the relative quantiﬁcation of TLR-4,
TLR-2, MyD88, TRAF6, TNF-α, IL-1β, IL-17, MMP-13 and iNOS. PCR
RealTime was performed by means of ready-to-use assays (Assays on
demand, Applied Biosystems, Carlsbad, CA, USA) on both targets and
endogenous controls. The ampliﬁed PCR products were quantiﬁed by
measuring the calculated cycle thresholds (CT) of TLR-4, TLR-2,
MyD88, TRAF6, TNF-α, IL-1β, IL-17, MMP-13, iNOS, and β-Actin
mRNA. The amounts of speciﬁc mRNA in samples were calculated by
the ΔΔCT method. The mean value of normal cartilage target levels
became the calibrator (one per sample) and the results are expressed
as the n-fold difference relative to normal controls (relative
expression levels).
2.7. Western blot assay of TLR-4, TLR-2, MyD88 and TRAF6 proteins
For SDS-PAGE and Western blotting, the cartilage samples were
washed twice in ice-cold PBS and subsequently dissolved in SDS
sample buffer (62.5 mM Tris/HCl, pH 6.8, 2% w/v SDS, 10% glycerol,
50 mM dithiothreitol, 0.01% w/v bromophenol blue). Aliquots of
whole cell protein extract (10–25 μL/well) were separated on a mini
gel (10%). The proteins were blotted onto polyvinylidene diﬂuoride
membranes (GE Healthcare, Buckinghamshire, UK) using a semi-dry
apparatus (Bio-Rad, Hercules, CA, USA). The membranes were then
incubated overnight in a roller bottle with the speciﬁc diluted
(1:1000) primary antibody in 5% bovine serum albumin, 1× PBS,
and 0.1% Tween 20 at 4 °C. After being washed in three stages in wash
buffer (1× PBS, 0.1% Tween 20), the blots were incubated with the
diluted (1:2500) secondary polyclonal antibody (goat anti-rabbit
conjugated with peroxidase), in TBS/Tween-20 buffer, containing 5%
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washed ﬁve times in wash buffer, and the proteins, after coloration
with DAB liquid substrate (Sigma-Aldrich, Milan, Italy) were made
visible using a UV/visible transilluminator (EuroClone, Milan, Italy)
and Kodak BioMax MR ﬁlms. A densitometric analysis was also run in
order to quantify each band.
2.8. NF-kB p50/65 transcription factor assay
NF-kB p50/65 DNA binding activity in nuclear extracts of cartilage
tissue samples was evaluated in order to measure the degree of NF-kB
activation. Analysis was performed in line with the manufacturer's
protocol for a commercial kit (NF-kB p50/65 Transcription Factor
Assay Colorimetric, cat. no. SGT510, Chemicon International Inc.,
Temecula, CA USA). Cartilage samples dissected from hind limb joints
were ﬁrst plotted, using an automatic potter (Mod.8533 Automatic
Potters, B. Braun, Melsungen AG, Germany), in order to isolate all
cartilage cells. An aliquot of these cells (4–5×105) was used for NF-kB
assay. Cytosolic and nuclear extraction was performed by lysing
the cell membrane with an apposite hypotonic lysis buffer (20 mM
Tris–HCl pH 7.5, 150 mM NaCl, 1.0 mM EDTA, 1.0 mM EGTA, 1.0%
Triton, 2.5 mM Na4P2O7. 1.0 mM β-glycerophosphate, 1.0 mM
Na3VO4) containing protease inhibitor cocktail and tributylphosphine
(TBP) as reducing agent. After centrifugation at 8000×g, the
supernatant containing the cytosolic fraction was stored at −70 °C,
while the pellet containing the nuclear portion was then re-
suspended in the apposite extraction buffer (25 mM HEPES pH 7.5,
500 mM NaCl, 1.0 mM DTT, 10 mM NaF, 10% Glycerol, 0.2% NP40,
5.0 mM MgCl2) and the nuclei were disrupted by a series of drawing
and ejecting actions. The nuclei suspension was then centrifuged at0
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Fig. 1. Effect of HA treatment on the development (A) and progression (B) of arthritis at
the end of experiment (day 50). Evaluation was performed on day 50. Values are the
mean±S.D. of seven experiments. °pb0.001 vs Control; *pb0.005 and **pb0.001 vs CIA.16,000×g. The supernatant fraction was the nuclear extract. After the
determination of protein concentration, this extract was stored in
aliquots at −80 °C for the subsequent NF-kB assay. After incubation
with primary and secondary antibodies, color development was
observed following the addition of the substrate TMB/E. Finally, the
absorbance of the samples was measured using a spectrophotometric
microplate reader set at λ 450 nm. Values are expressed as relative
optical density (OD)/mg protein.
2.9. TNF-α, IL-1β, IL-17, MMP-13 and iNOS ELISA assay
Samples of cartilage obtained frommice hind limbs in the presence
of 1.0 nM PMSF and protease inhibitor cocktail were ﬁrst lysed using
an opportune hypotonic lysis buffer (20 mM Tris–HCl pH 7.5, 150 mM
NaCl, 1.0 mM EDTA, 1.0 mM EGTA, 1.0% Triton, 2.5 mM Na4P2O7.
1.0 mM β-glycerophosphate, 1.0 mM Na3VO4, 0.2% TBP) and then
centrifuged at 13,000 rpm for 10 min at 4 °C. The analysis of TNF-α,
IL-1β, and IL-17 was carried out using a speciﬁc commercial kit.
Brieﬂy, 50 μL of standards, samples and controls was added to each
well of the coated microplate. 50 μL of each speciﬁc biotin-conjugate
antibody was then added to each well. After 120 min of incubation at
20–22 °C, the liquid from the wells was discarded, the wells were
washed three times and 100 μL of Streptavidin-HRP was added. After
further incubation for 60 min and washing the wells again, 100 μL of a
substrate chromogen solution was added. After 10 min incubation0
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Fig. 2. Effect of HA treatment on articular cartilage TLR-4 mRNA expression (A) and
related protein production (B, C) in joints of mice with CIA. Values are the mean±S.D.
of seven experiments and are expressed as the n-fold increase with respect to the
Control (A) and as both densitometric analysis (C) andWestern blot analysis (B) for the
TLR-4 protein levels. °pb0.001 vs Control; *pb0.01, **pb0.005 and ***pb0.001 vs CIA.
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well was read spectrophotometrically at λ 450 nm. TNF-α IL-1β and
IL-17 values are expressed as pg/mg protein. For MMP-13 and iNOS,
100 μL of previously diluted samples, standards and controls was
added to eachwell of the coatedmicroplate. After incubation for 2 h at
37 °C, the liquid of each well was discarded. After adding 100 μL of the
detection reagent A and incubation at 37 °C for 1 h, the liquid was
aspirated and wells were washed with wash buffer. At this point,
100 μL of detection reagent B was added to each well, and after a
further incubation for 1 h at 37 °C the liquid of wells was ﬁrst aspired
then wells were washed with wash buffer. 90 μL of the substrate
solution was added and after incubation at room temperature for
30 min, 50 μL of stop solution was added. The absorbance of each well
was read, within 30 min, spectrophotometrically at λ 450 nm. MMP-
13 values are expressed as pg/mg protein, while iNOS values are
expressed as U/mg protein.
2.10. HA assay
HA analysis was performed in plasma and synovial ﬂuid samples
obtained at day 35 and at the end of the experiment (day 50). The
assay was carried out using a speciﬁc enzyme-linked binding protein
assay test kit (Hyaluronan ELISA kit, cat no. K-1200, Echelon0
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Fig. 3. Effect of HA treatment on articular cartilage TLR-2 mRNA expression (A) and
related protein production (B, C) in joints of mice with CIA. Values are the mean±S.D.
of seven experiments and are expressed as the n-fold increase with respect to the
Control (A) and as both densitometric analysis (C) andWestern blot analysis (B) for the
TLR-2 protein levels. °pb0.001 vs Control; *pb0.01, **pb0.005 and ***pb0.001 vs CIA.Biosciences Inc., Salt Lake City, UT, USA). In brief, samples were
added to a microtiter well together with an antibody-like peptide and
incubated at room temperature for 1 h. After washing, a secondary
antibody conjugated with peroxidase (HRP-conjugated) directed
against this latter was added to the well and incubated at room
temperature for 30 min. Subsequently, after adding a one-component
substrate solution (3,3′,5,5′-tetramethylbenzydine plus hydrogen
peroxide) and a further incubation period (at room temperature for
30 min) the reaction was stopped with 0.36 N H2SO4 and the
absorbance was read at 450 nm using a microplate reader (DAS srl,
Rome, Italy). The concentration of HA in each sample was determined
by interpolation from a standard curve ranging from 0.0 to 800.0 ng/mL
for plasma levels and from 0.0 to 100.0 μg/mL for synovial ﬂuid levels.2.11. HA size analysis
The HA size was evaluated on agarose gel (1.0%, 1xTAE buffer,
30 V) using a previously published method [29]. Five milliliters of
each sample was ﬁrst dried in a vacuum drier (CentriVap Console,
Labconco, Kansas City, MO, USA) and the pellet was resuspended with
10 μL of buffered solution and then loaded per lane. Deﬁned DNA
ladder (100 bP, Stratagene, La Jolla, CA, USA) and HA molecular0
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run as standards. Bands were then stainedwith Stains-All dye (0.005%
w/v in ethanol). After electrophoresis, the gel was removed from the
apparatus and was illuminated in a dark room connected up to a
digital camera (mod. Coolpix 4500, Tokyo, Japan). Data were acquired
and processed by the computer using a speciﬁc data acquisition
program (Nikon view 5, Nikon, Tokyo, Japan).0
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Fig. 6. Effect of HA treatment on articular cartilage NF-kB p50/65 transcription factor
DNA binding activity in joints of mice with CIA. White bars represent the p/50 subunit,
and black bars represent the p/65 subunit. Values are the mean±S.D. of seven2.12. Histology
At the end of the experimental phase, knee joints were removed
from the hind limbs of the animals andﬁxedwith 4% paraformaldehyde
in 0.1 M phosphate buffer, pH 7.4, at 4 °C for 4 h, and then washedwith
0.2 M phosphate buffer, pH 7.4. The specimens were decalciﬁed with a
ready to use decalciﬁer solution (Cal-Ex, Thermo Fisher Scientiﬁc,
Waltham, MA, USA) for 6 h, dehydrated in graded ethanol and
embedded in a special tissue embedding media (Paraplast, McCormick
Scientiﬁc, Richmond, VA, USA). Traditional histological sections (7 μM)
were cut with amicrotome (mod. RM 2125 RT, Leica Camera AG, Solms,
Germany), stained with Hematoxylin–Eosin technique and viewed and
photographed with a light microscope (mod. BH2, Olympus America
Inc., Melville, NY, USA).0
5
10
°
TR
A
F6
 D
en
sit
om
et
ri
c
a
n
a
ly
sis
(ar
bi
tr
ar
y
u
n
its
)
B
0
5
10
TR
A
F6
 m
R
N
A
 (n
-
fo
ld
in
cr
ea
se
o
f c
o
n
tr
ol
)
°
*
**
A
***
***
*
**
C
CTRL HA                CIA               CIA + HA        CIA + HA          CIA + HA 
40 mg/kg                               10 mg/kg        20 mg/kg 40 mg/kg      
β-actin
CTRL HA CIA CIA + HA CIA + HA CIA + HA
40 mg/kg 20 mg/kg 40 mg/kg10 mg/kg
CTRL HA CIA CIA + HA CIA + HA CIA + HA
40 mg/kg 20 mg/kg 40 mg/kg10 mg/kg
Fig. 5. Effect of HA treatment on articular cartilage TRAF6 mRNA expression (A) and
related protein production (B, C) in joints of mice with CIA. Values are the mean±S.D.
of seven experiments and are expressed as the n-fold increase with respect to the
Control (A) and as both densitometric analysis (C) andWestern blot analysis (B) for the
TRAF6 protein levels. °pb0.001 vs Control; *pb0.01, **pb0.005 and ***pb0.001 vs CIA.
experiments and are expressed as optical density at λ 450 nm/mg protein of nuclear
extract. °pb0.001 vs Control; *pb0.005 and **pb0.001 vs CIA.Cartilage destruction was measured as cartilage thickness and
cartilage surface erosion in serial sections of each knee joint. Cartilage
thickness was determined as absolute value of the layer obtained in0
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determined as the amount of cartilage lost in the relation to the total
cartilage area. All experiments were scored separately and indepen-
dently of each other. Data were expressed as the mean of all cartilage
layers measured [30].2.13. Protein analysis
The amount of protein was determined using the Bio-Rad protein
assay system (Bio-Rad Lab.., Richmond, CA, USA) with bovine serum
albumin as a standard in accordance with the published method [31].2.14. Statistical analysis
Data are expressed as means±S.D. of no less than seven
experiments for each test. Statistical analysis was performed by
one-way analysis of variance (ANOVA) followed by the Student–
Newman–Keuls test. The statistical signiﬁcance of differences was set
at pb0.05.2.15. Statement of animal care
The studies reported in this manuscript have been performed out
in accordancewith the Helsinki declaration and the NIH guidelines for
the Care and Use of Laboratory Animals.0
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3.1. Effects of HA treatment on clinical signs of CIA
On about day 20, animals began to show evidence of clinical
inﬂammation in one or more hind paws. The ﬁrst manifestation of
disease was erythema of one or more ankle joints, followed by the
metatarsal and interphalangeal joints. Fig. 1A reports the incidence of
CIA over the 50-day study period. The initial signs of arthritis were
evident at day 25 in all mice treated with CIA. In the CIA-group
untreated with HA, the percentage of mice developing arthritis was
98% at day 25 and the same percentage was maintained up until the
end of the experiment. Treatment with HA signiﬁcantly attenuated
the development of CIA: 15% with the dose of 10 mg/kg; 27% with the
dose of 20 mg/kg and, 43% with the dose of 40 mg/kg (Fig. 1A).
The end of the experiment is presented in Fig. 1B which shows the
ﬁnal stage of the disease, as assessed by the arthritis evaluation scale.
By day 25 all animals showed evidence of the disease, predominantly
in the hindpaws. The disease progressed continuously with joint
recruitment following an identical pattern: tarsal, metatarsophalan-
geal followed by interphalangeal. The interphalangeal joints were
never affected alone, and inﬂammation in these joints was invariably
associated with inﬂammation in the tarsal joint. The arthritis score in
CIA mice was progressive from day 25 and reached an arthritis index
score of about 12.7 in the ﬁnal week. The same changeswere observed
in the hind paw diameter of CIA animals. Administration of HA
signiﬁcantly attenuated all clinical signs of arthritis: a.i.=8.2 with the
dose of 10 mg/kg, a.i.=6.7 with the dose of 20 mg/kg and a.i.=5.4
with the dose of 40 mg/kg (Fig. 1B).0
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analysis
TLR-4, TLR-2, MYD88 and TRAF-6 (Figs. 2, 3, 4 and 5) mRNA
evaluation (panel A of each ﬁgure) and Western blot analysis with
densitometric evaluation (Figs. 2, 3, 4 and 5, panels B and C of each
ﬁgure) were assayed in order to estimate the degree of TLR-4 and TLR-
2 activation and the consequent cell signaling pathway booster that
culminates in NF-kB factor activation. Very low gene expression and
the related protein production of TLR-4, TLR-2, MYD88 and TRAF-6
were obtained in non-arthritic mice (CTRL and CTRL+HA). In
contrast, a marked increase in the expression and protein synthesis
of the TLR-4 and TLR-2 and their signal mediators MYD88 and TRAF-6
was found in the cartilage joint of arthritic mice. Both TLR-4 and TLR-2
were highly expressed and this means that both receptors were
involved in this pathology.
The treatment with high molecular weight HA for 30 days
produced a signiﬁcant reduction in the activation of both receptors
and their signal mediator levels in CIA-treated mice. As reported in
Figs. 2, 3, 4 and 5, HA treatment decreased TLR-4, TLR-2, MYD88 and
TRAF-6 expression and protein synthesis at all concentrations used in
a dose-dependent manner.
3.3. NF-kB activation
Fig. 6 shows the changes in the NF-kB p50/p65 heterodimer
translocation over the course of the experiment. NF-kB DNA binding
was present at very low levels in the joint cartilage of mice not subject
to CIA. In contrast, arthritis induced massive NF-kB translocation into
the nucleus of the damaged cartilage cells; the chronic treatment of0
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3.4. TNF-α, IL-1β, IL-17, MMP-13 and iNOS mRNA expression and
Western blot analysis
TNF-α, IL-1β, IL-17, MMP-13 and iNOS were assayed because of
their active role in inﬂammation and cartilage destruction. (Figs. 7, 8,
9, 10 and 11). Their mRNA evaluation (panel A of each ﬁgure) and
protein concentration (panel B of each ﬁgure) showed that the mRNA
of these inﬂammatory mediators was not stimulated in the joint
cartilage of mice not subject to CIA and protein level was also very
low. However, in themice subjected to CIA, TNF-α, IL-1β, IL-17, MMP-
13 and iNOS expression and the related protein concentration were
signiﬁcantly up-regulated. The administration of high molecular
weight HA was able to reduce this increment in mRNA expression
at all doses. As reported (Figs. 7, 8, 9, 10, and 11; panels A and B of each
ﬁgure), the increase in mRNA expression of TNF-α, IL-1β, IL-17, MMP-
13 and iNOS in arthritic mice correlated well with the increment in
protein synthesis. This correlation was also maintained in mice
treated with HA. In fact, the reduction in mRNA expression resulted in
a similar diminution in protein formation.
3.5. Histological analysis
Fig. 12 reports a representative joint histopathology of all the
experimental groups. Panels A and B show a knee joint section from
mice not subject to CIA. The fully stained cartilage layers indicate no0
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Fig. 12. Effect of HA on matrix proteoglycan loss and erosion in joint cartilage. Evaluation was performed at the end of the experiment, on day 50. Hematoxylin–Eosin staining
(magniﬁcation 2080×).
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CIA-treated mouse. This clearly shows the severe knee joint
inﬂammation and loss of Hematoxylin–Eosin staining of the cartilage
layers, as well as the complete disruption of the original cartilage
architecture (indicated by triangles). In panels D, E, and F a
representative selection of knee joint sections from mice receiving
CIA and HA treatment shows that a gradual reduction in joint damage
and cartilage erosion occurred. As indicated by arrows HA adminis-
tration reduced cartilage thickness and jagged margins (Fig. 12).
We also quantiﬁed cartilage thickness and surface erosion in the
same sections (Fig. 13, panels A and B). In control groups no loss of
cartilage was seen. On the contrary, mice with arthritis showed a
massive reduction on cartilage thickness and increase in surface
erosion; the treatment of CIA-mice with HA, at different doses, was
able to prevent signiﬁcantly cartilage loss.
3.6. Plasma and synovial HA levels
HA concentrations were measured in control and CIA mice HA
treated/untreated in order to compare the protective effect associated
with enhanced HA plasma and synovial ﬂuid levels and biochemical
and histological parameters (Fig. 14, panels A, B, C, and D). Consistent
with previous studies, plasma and synovial ﬂuid levels of HA were
signiﬁcantly higher in mice underwent to CIA and untreated with HA
with respect CTRL-mice. The treatment with HA was able to increase
plasma and synovial ﬂuid HA levels both at 35 days (15 daystreatment) and at 50 days (30 days treatment). The HA increase was
also signiﬁcant both in CIA-mice and in CTRL-mice treated with HA
(Fig. 14, panels A, B, C, and D). Comparison of HA levels inmice treated
with CIA suggested a possible trend for positive correlation with
biochemical and histological parameters as well as with the HA doses
chronically administered.
3.7. HA molecular weight
Fig. 15 shows the detection of HA fragment size in synovial ﬂuid at
the end of the experiment. CTRLmice presented a comparable amount
of HA at both low and high molecular weights. On the contrary CTRL
mice treated with HA presented an increase in HA content at high
molecular weight. CIA mice mainly presented high percentage of low
molecular weight HAwith respect to highmolecular weight HA, while
the treatment of CIA mice, as well as CTRL mice, was particularly able
to increase the content of HA at high molecular weight (Fig. 15). The
increase of HA at high molecular weight was positively correlated
with the corresponding HA dose chronically administered, while the
increase of HA at low molecular weight could be associated with the
increase in inﬂammation found in CIA mice untreated with HA.
4. Discussion
Chronic inﬂammation is a signiﬁcant factor in the pathophysiology
of many forms of joint disease. Both the most commonly diagnosed
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diseases of the joints and progressive loss of cartilage is a
characteristic feature of these diseases. Therefore, chondroprotection
of the cartilage is one of the most important goals to achieve in this
ﬁeld. It is acknowledged that cartilage homeostasis results from the
balance between its anabolic and its catabolic rates. Cartilage
depletion occurs in RA through both the breakdown of the matrix
and the reduced synthesis of its macromolecular components. The
ongoing challenge is to deﬁne the catabolic triggers of articular
chondrocytes in the pathogenesis of cartilage degradation in various
arthritic diseases. Previous studies showed that TLRs such as TLR-2
and TLR-4 are expressed in the synovium of patients with long-
standing RA [8,32,33]. When TLRs (except TLR-3) recognize PAMPs,
the myeloid differentiation primary response protein (MyD88) binds
to the Toll/IL-1 receptor (TIR) domain of TLRs, which triggers the
intracellular interleukin-1 receptor (IL-1R) family signaling cascade.
The activation of nuclear factor kappaB (NF-kB) and mitogen-
associated protein kinase (MAPK) cascades involves a signaling
complex that contains MyD88, IL-1R-associated kinase (IRAK) and
tumor necrosis factor receptor-associated factor 6 (TRAF-6) [34,35].
Lastly, transcription is initiated to express several pro-inﬂammatory
cytokines and effector cytokines, such as interferon-alpha/beta
(IFN-α/β), interleukin-6 (IL-6), interleukin-1beta (IL-1β), and tumor
necrosis factor-alpha (TNF-α) or other inﬂammatory molecules, such
as nitric oxide (NO) produced by the inducible nitric oxide synthetase
(iNOS), reactive oxygen species (ROS) and metalloproteinases
(MMPs) [36,37].
Considering the role of TLRs as a critical link between the innate
and the adaptative immune response, it is plausible to hypothesizethat continuous activation or dysregulation of TLR signaling might
contribute to the pathogenesis of autoimmune diseases such as RA or
OA. In fact, stimulation of TLR-2 and TLR-4 pathways in synovial
ﬁbroblasts obtained from patients with RA leads to translocation of
NF-kB, and secretion of pro-inﬂammatory cytokines, MMPs and other
chemokines [8,32,33]. Chondrocytes respond to the pro-inﬂammatory
stimuli by increasing the production of proteinases, prostaglandins,
and nitrogen oxide (NO) [38]. In experimental models of arthritis, TLR
ligands are used repeatedly to induce the disease in susceptible
animals; for instance, intra-articular injection of streptococcal cell
wall fragments, or double-stranded RNA, whichmainly signal through
TLR-2, and TLR-3, respectively, can induce arthritis [39,40]. Further-
more, LPS from the outer membrane of gram-negative bacteria,
signaling through TLR-4, is used extensively to aggravate or reactivate
arthritis in distinct animal models [41,42]. It was previously reported
that TLRs can also be activated by several endogenous ligands that are
released from stressed or damaged host tissue. In this context, TLR-4
can recognize extracellular matrix components such as heparan
sulfate and extra domain A of ﬁbronectin [43,44] and both TLR-2 and
TLR-4 can recognize the matrix component biglycan [45]. TLR
activation by these self antigens can potentially promote the develop-
mentof autoimmunediseases.On the contrary, inhibitingTLR activation
seems to be an important strategy to reduce cellular injury and it may
reduce inﬂammation in arthritis in particular [46,47].
HA is a component of the ECM in various tissues, and is essential
for matrix assembly and ﬂuid viscosity in cartilage. HA has been
reported to exhibit cartilage-protective effects, including stimulation
of chondrocyte proliferation, production of cartilage matrix, and
inhibition of protease [48], and it also seems to be a potent
inﬂammatory agent [15–88, 25].
This double role played by HA seems to be due to its molecular
mass, and its effects seem, in part, to be related to its interaction with
TLR-4 [15–18].
In a previous experiment we started HA administration two weeks
after the arthritic signs were well developed, and continued, daily, for
30 days (unpublished data). Unfortunately, although a slight signif-
icant protection was seen, mainly by the histological evaluation, the
reduction of TLR-4 and TLR-2, and other inﬂammatory intermediates
such as TNF-α, IL-6, MMP-13, and iNOS produced not evident effects.
This could be explained by the fact that when the disease is well-
established, different mechanism, other than TLRs, could be involved
in the chronic inﬂammation, and therefore the block/modulation of
these receptors, responsible of the early phase of inﬂammation, may
assume a secondary role in the chronic inﬂammation, typical of
arthritis. On the contrary, HA treatment of mice at onset of CIA
development may contrast the early mechanisms responsible of
inﬂammation that then culminate with cartilage/bone erosion and
chronic inﬂammation. Therefore, high molecular weight HA seems to
reduce arthritis at early stage of development by blocking the
initiators of the inﬂammatory response, while, by this same way,
may not when disease is fully developed. In this context the large use
of HA, by joint injection, in human RA and OAmay be also considered,
with good results and mainly pain and swelling reduction [49]. In this
case the mechanism could be different, as the local injection may
provide a high HA concentration to the inﬂamed joints. In addition, as
HA binds large amounts of H2O, the joint amelioration may be due
especially to its rheological/ﬂuidizing properties than to a direct
interaction with receptor or other protein structures, although other
speciﬁc unknown interactions couldn't excluded.
In fact, intra-articular treatment with HA and hylans has become
more widely accepted in the range of therapies to combat OA and RA
pain [49]. HA is directly responsible for the viscoelastic properties of
synovial ﬂuid. Thus, it seems that the goal of intra-articular therapy
with HA is to help replace synovial ﬂuid that has lost its viscoelastic
properties. Although exogenous HA therapy may exert this effect, the
effective protective action of HA is not fully understood.
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1179G.M. Campo et al. / Biochimica et Biophysica Acta 1812 (2011) 1170–1181In the present study, the treatment of arthritic mice with different
doses of high molecular weight HA was able to reduce inﬂammation
and cartilage erosion induced by CIA, as also shown in our previous
experiments on different types of animal [27,28]. This study examined
the effects of the prolonged intra-peritoneal administration of high
molecular weight HA, at different molecular concentrations, on TLR-2
and TLR-4modulation in arthritic mice. Our ﬁndings suggest that both
receptors were involved in this experimental disease and that HA
reduced TLR-2 and TLR-4 expression and the inﬂammatory mecha-
nism primed by their activation. Indeed, the data obtained show that
the HA was able to reduce the expression of the two receptors, their
intermediates whereby NF-kB is activated, and a series of mediators of
inﬂammation and cartilage degradation. The effects were well
substantiated by the dose-dependent efﬁcacy exerted by HA. In CIA-
treated mice, HA was able to reduce not only the expression of TLR-2
and TLR4, MyD88 and TRAF6 but also NF-kB activation and the
increment in pro-inﬂammatory cytokines TNF-α, IL-1β and IL-17,
MMP-13 and iNOs. These ﬁndings were further conﬁrmed by the
histological results, where cartilage degradation was limited by HA
treatment. A further support to these data can be given from the
analysis of HA levels in plasma and synovial ﬂuid that well correlated
with biochemical and histological parameters. The increment in
synovial ﬂuid of HA at high molecular weight in mice chronicallyadministered with HA conﬁrms the protective role exerted by this
polymer in modulating TLR-2 and TLR-4.
The interaction of cells with the surrounding ECM is fundamental in
many physiological and pathological mechanisms. Proteoglycans may
inﬂuence cell behavior through binding events mediated by their GAG
chains. The speciﬁcity of protein–GAG interactions is governed by the
ionic attractions of sulfate and carboxylate groups of GAGs toward the
basic amino acid residues on the protein as well as by the optimal
structural ﬁt of the GAG chain into the protein binding site [50]. The
binding afﬁnity of the interaction depends on the ability of the
oligosaccharide sequence to provide an optimal charge and surface
with the protein [51]. It has been demonstrated that the interaction of
HA degradation products with TLR-2 and TLR-4 provides signals to
initiate inﬂammation after non-infectious lung injury, whereas TLR-2
and TLR-4 serve to maintain epithelial cell integrity and tissue repair by
sensing native high-molecular-mass HA [15]. Other data support the
idea that a balance between low molecular weight HA and high
molecular weight HA, by engaging TLR-2, may control the activation of
the innate immune response in situations of tissue damage and danger
[51]. In fact, in the event of tissue destruction, highmolecularweightHA
is broken down into low molecular weight HA species which have the
ability to promote inﬂammation by inducing the release of reactive
oxygen species, such as NO, cytokines, such as TNF-α and IL-1β, and
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1180 G.M. Campo et al. / Biochimica et Biophysica Acta 1812 (2011) 1170–1181destructive enzymes, such as MMPs and by facilitating the recruitment
of CD44+ leukocytes [17,52]. While high molecular weight HA
maintains homeostasis and potentially down-regulates inﬂammation,
the generation of low molecular weight HA may act as an endogenous
danger signal, leading to the activation of both innate and acquired
immunity. The fact that a lack of low molecular weight HA clearance
leads to excess damage, whereas the over-expression of highmolecular
weight HA is protective in the non-infectious lung injury model
supports this hypothesis [11,15,53]. Although PAMPs alert the immune
system to exogenous pathogens andmolecules like uric acid and others
signal necrotic cell death, low molecular weight HA heralds a breach of
barriers and the destruction of tissue integrity [54]. In this way, low
molecularweight HA-induced TLR signalingmight activate the immune
response before the development of an established infection or necrotic
cell death. Although there is a constant turnover of high molecular
weight HA in the day-to-day maintenance of a normal matrix, it is
rapidly degraded into very small non-biologically active fragments
which are quickly cleared by the liver [10]. Therefore, the positive
modulatory effect exerted by high molecular weight HA on all the
parameters considered could be due to its efﬁciency in binding protein
structures, such as TLR-2 and TLR4, thereby exerting a block that
prevents receptor stimulation by the speciﬁc ligands produced during
arthritis. We previously reported that medium molecular weight HA
does not exert any protective/inﬂammatory action on chondrocytes
stimulatedwith LPS [18]. This could be explainedby the hypothesis that,
as its structure is probably unable tomask the TLRs studied or to act as a
TLR agonist, it is therefore not able to reduce or to stimulate production
of pro-inﬂammatory and degradative mediators. We suggest that the
number of interaction sites available in the HA structures may play the
key role inHAmodulatory activity during the inﬂammatorymechanism.
From these ﬁndings we may thus conclude that high molecular weight
HA via its polymerized structure may mask TLR-2 and TLR-4 thereby
preventing the stimulation of this receptor by other agents and the
consequent activation of NF-kB that culminates in the transcription of
the detrimental mediators responsible for arthritic injury.
However, further studies are needed to fully conﬁrm these
hypotheses.Acknowledgements
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